AFT Pharmaceuticals has reported
its first annual result since being
publicly listed (PD 11 Dec 2015),
with revenue up 14% to $64m and
an $8.9m loss for the year to 31 Mar.
Almost all of the loss is attributed
to an accelerated research and
development program, with ceo
Hartley Atkinson saying he expects
losses to continue for the next
couple of years due to “significant
investment in accelerating
clinical studies for key innovative
products”.
He said the proposed down-scheduling
of Maxigesic to
pharmacy-only, along with up-scheduling
of competitor OTC
codeine combination products
offers a strong upside for the
product in the Australian market.
Australian revenue grew 19%
to $31.2 million, with a strong
increase in the main OTC channel.
Atkinson also hailed the deal with
the Pharmacy Guild which will see
the Gold Cross endorsement on
Maxigesic 24-tablet packs.The above article was sent to subscribers in Pharmacy Daily's issue from 26 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 May 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.